Impact of consolidative HSCT after CAR T-cell–induced remission in pediatric relapsed/refractory B-ALL: a single-center retrospective cohort

医学 回顾性队列研究 造血干细胞移植 队列 儿科 比例危险模型 内科学 生存分析 队列研究 癌症 疾病 总体生存率 肿瘤科 移植 嵌合抗原受体 完全缓解 年轻人 儿童癌症 外科
作者
Ziwei Liao,Feimei Kuang,Yuxuan Luo,Jiayi Wang,Wenge Hao,Qingqing Zheng,林慧玲,Pengfei Wang,Hua Jiang,Weina Zhang
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:16: 1866852-
标识
DOI:10.3389/fonc.2026.1866852
摘要

Background Whether allogeneic hematopoietic stem cell transplantation (HSCT) is required after chimeric antigen receptor T-cell (CAR-T)–induced remission in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains unresolved. We report single-center outcomes of CAR-T therapy with or without subsequent HSCT, evaluated using current consensus response criteria. Methods This single-center retrospective cohort study included 34 pediatric patients with R/R B-ALL who received investigational autologous CAR-T products (CD28- or 4-1BB–based; single- or dual-target) between June 2018 and December 2023. Response was assessed per National Comprehensive Cancer Network guidelines and international consensus definitions; survival by Kaplan–Meier estimation. The HSCT comparison was descriptive, complemented by a 6-month landmark analysis, a time-dependent Cox analysis restricted to patients transplanted at our center, and event-free survival (EFS) with in-remission HSCT censored at transplant. Results Median age was 7.3 years; 26 patients were relapsed and 8 refractory. CR or CRi (CR/CRi) was achieved in 26/34 (76.5%), all MRD-negative. Grade ≥3 CRS occurred in 11.8% and grade 3 ICANS in 2.9%. At a median follow-up of 21.4 months, 2-year OS and EFS were 57.4% (95% CI, 38.8–72.3) and 43.2% (26.2–59.1). Among 24 patients with marrow-involved disease achieving MRD-negative CR, 20 underwent HSCT and 4 did not; 2-year OS was 79.3% versus 25.0% (descriptive log-rank P = 0.006), and all 4 non-HSCT patients relapsed and died. In the 6-month landmark analysis (n=21), HSCT by landmark remained associated with superior OS (P = 0.047); the time-dependent Cox analysis showed a consistent association (OS: HR, 0.19 (0.04–0.90); P = 0.036). With in-remission HSCT censored, no patient remained event-free beyond 12.1 months, versus a conventional 2-year EFS of 61.8%. Two of 4 patients with isolated testicular relapse achieved durable remission without HSCT. Conclusions CAR-T therapy induced high rates of MRD-negative remission with manageable toxicity in pediatric R/R B-ALL, but rarely produced durable survival without HSCT in marrow-involved disease. Post-remission HSCT was associated with improved survival; salvage HSCT after relapse also appeared effective in a few patients. These associations are limited by the retrospective design and small sample size and require prospective confirmation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
Bob发布了新的文献求助10
1秒前
Mong那粒沙完成签到,获得积分10
1秒前
fsgdf完成签到,获得积分10
2秒前
2秒前
搜集达人的应助被雪中漫步采纳,获得10
3秒前
3秒前
肉丝完成签到,获得积分10
4秒前
锂享生活发布了新的文献求助30
5秒前
clear完成签到,获得积分10
5秒前
Jin关注了科研通微信公众号
6秒前
你说吧完成签到,获得积分10
7秒前
7秒前
7秒前
慕雪完成签到,获得积分10
7秒前
7秒前
8秒前
王乐乐发布了新的文献求助10
8秒前
711moiii发布了新的文献求助10
8秒前
Charlee完成签到,获得积分10
8秒前
ylin完成签到,获得积分10
9秒前
Kobe完成签到,获得积分10
9秒前
所所的应助被WYL采纳,获得10
9秒前
陈龙发布了新的文献求助10
9秒前
研友_VZG7GZ的应助被吟风采纳,获得10
10秒前
fei发布了新的文献求助10
11秒前
fleeting完成签到 ,获得积分10
12秒前
光亮凉面完成签到,获得积分10
12秒前
田様的应助被小Z采纳,获得10
13秒前
兰亭金谷关注了科研通微信公众号
13秒前
123完成签到,获得积分10
14秒前
14秒前
mmmml发布了新的文献求助10
14秒前
14秒前
15秒前
15秒前
Nole的应助被连钧采纳,获得10
15秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192141
求助须知:如何正确求助?哪些是违规求助? 9578771
关于积分的说明 21861764
捐赠科研通 7791657
什么是DOI,文献DOI怎么找? 3436846
关于科研通互助平台的介绍 2560547
邀请新用户注册赠送积分活动 2483605